Bedford, MA - Ocular Therapeutix, Inc. announced today that it has received IDE approval from the U.S. Food and Drug Administration to conduct a pivotal clinical trial with ReSure Sealant, a … [Read more...]

Bedford, MA - Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with … [Read more...]

Plugs achieved 100% retention and demonstrated sustained levels of moxifloxacin throughout the 10-day treatment period. Bedford, MA - Ocular Therapeutix, Inc. announced today the completion of a … [Read more...]

Waltham, MA - Ocular Therapeutix, Inc. announced today the expansion of its board of directors with the appointment of Mr. Daniel Myers and Mr. Bernard Haffey. Mr. Myers is currently the … [Read more...]

Waltham, MA - I-Therapeutix, Inc. announced today that it has changed its corporate name to Ocular Therapeutix, Inc. Amar Sawhney, President and CEO-stated “the Company’s new name more clearly … [Read more...]

Waltham, MA - I-Therapeutix announced today that it has closed a $15million dollar Series C financing. The round was led by Polaris Venture Partners inWaltham, MA, with continued participation by … [Read more...]

Waltham, MA - I-Therapeutix, Inc. announced today that Mr. Richard Packard and Dr. Daniel Calladine from the Prince Charles Eye Unit, King Edward VII Hospital, Windsor, UK, performed the first … [Read more...]